Neutralizing capacity of monoclonal antibodies that recognize peptide sequences underlying the carbohydrates on gp41 of simian immunodeficiency virus

Journal of Virology

Volumn 86, Issue 23, 2012, Pages 12484-12493

  Martinez Navio, José M ^a   Desrosiers, Ronald C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4G8; MONOCLONAL ANTIBODY 6G8; MONOCLONAL ANTIBODY 7D6; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY ISOLATION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN GLYCOSYLATION; RHESUS MONKEY; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SIMIAN IMMUNODEFICIENCY VIRUS; STRUCTURE ANALYSIS; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS PARTICLE; WESTERN BLOTTING;

AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; GENE PRODUCTS, ENV; GLYCOSYLATION; HUMANS; MACACA MULATTA; NEUTRALIZATION TESTS; PEPTIDES; SEQUENCE ANALYSIS, DNA; SIMIAN IMMUNODEFICIENCY VIRUS;

MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84869216717     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01959-12     Document Type: Article

References (39)

1. Adekar SP, et al. 2008. Hybridoma populations enriched for affinitymatured human IgGs yield high-affinity antibodies specific for botulinum neurotoxins. J. Immunol. Methods 333:156-166.
2. Bixby JG, Laur O, Johnson WE, Desrosiers RC. 2010. Diversity of envelope genes from an uncloned stock of SIVmac251. AIDS Res. Hum. Retroviruses 26:1115-1131.
3. Brochet X, Lefranc MP, Giudicelli V. 2008. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 36:W503-W308.
4. Chaillon A, et al. 2011. The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12. J. Virol. 85:3642-3648.
5. Reference deleted
6. Chothia C, et al. 1989. Conformations of immunoglobulin hypervariable regions. Nature 342:877-883.
7. Cole KS, Steckbeck JD, Rowles JL, Desrosiers RC, Montelaro RC. 2004. Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3. J. Virol. 78:1525-1539.
8. Derby NR, et al. 2007. Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens. Virology 366:433-445.
9. Gibbs RA, et al. 2007. Evolutionary and biomedical insights from the rhesus macaque genome. Science 316:222-234.
10. Giudicelli V, Brochet X, Lefranc MP. 2011. IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. Cold Spring Harb. Protoc. 2011:695-715.
11. Hatada M, et al. 2010. Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2. J. Gen. Virol. 91:1335-1345.
12. Haynes BF, et al. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275-1286.
13. Johnson WE, et al. 2003. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J. Virol. 77:9993-10003.
14. Lefranc MP. 2001. Nomenclature of the human immunoglobulin genes. Curr. Protoc. Immunol. Appendix 1:Appendix 1P. doi:10.1002/ 0471142735.ima01ps40.
15. McCormack WT, Tjoelker LW, Stella G, Postema CE, Thompson CB. 1991. Chicken T-cell receptor beta-chain diversity: an evolutionarily conserved D beta-encoded glycine turn within the hypervariable CDR3 domain. Proc. Natl. Acad. Sci. U. S. A. 88:7699-7703.
16. Means RE, Greenough T, Desrosiers RC. 1997. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. J. Virol. 71:7895-7902.
17. Mori K, Ringler DJ, Kodama T, Desrosiers RC. 1992. Complex determinants of macrophage tropism in env of simian immunodeficiency virus. J. Virol. 66:2067-2075.
18. Mori K, et al. 2001. Quintuple deglycosylation mutant of simian immunodeficiencyvirus SIVmac239 in rhesus macaques: robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain. J. Virol. 75:4023-4028.
19. Morrison HG, Kirchhoff F, Desrosiers RC. 1993. Evidence for the cooperation of gp120 amino acids 322 and 448 in SIVmac entry. Virology 195:167-174.
20. Myers G, Lenroot R. 1992. HIV glycosylation: what does it portend? AIDS Res. Hum. Retroviruses 8:1459-1460.
21. National Research Council, Commission on Life Sciences. 1996. Guide for the Care and Use of Laboratory Animals, 7th ed. National Academies Press, Washington, DC.
22. Pikora CA. 2004. Glycosylation of the ENV spike of primate immunodeficiency viruses and antibody neutralization. Curr. HIV Res. 2:243-254.
23. Pommié C, Levadoux S, Sabatier R, Lefranc G, Lefranc MP. 2004. IMGT standardized criteria for statistical analysis of immunoglobulin V-REGION amino acid properties. J. Mol. Recognit. 17:17-32.
24. Postler TS, Martinez-Navio JM, Yuste E, Desrosiers RC. 2012. Evidence against extracellular exposure of a highly immunogenic region in the Cterminal domain of the simian immunodeficiency virus gp41 transmembrane protein. J. Virol. 86:1145-1157.
25. Reitter JN, Means RE, Desrosiers RC. 1998. A role for carbohydrates in immune evasion in AIDS. Nat. Med. 4:679-684.
26. Ruiz M, Lefranc MP. 2002. IMGT gene identification and Colliers de Perles of human immunoglobulins with known 3D structures. Immunogenetics 53:857-883.
27. Schultze JL, et al. 1995. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc. Natl. Acad. Sci. U. S. A. 92:8200-8204.
28. Scinicariello F, Engleman CN, Jayashankar L, McClure HM, Attanasio R. 2004. Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions. Immunology 111:66-74.
29. Sekaly RP. 2008. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J. Exp. Med. 205:7-12.
30. Sircar A, Kim ET, Gray JJ. 2009. RosettaAntibody: antibody variable region homology modeling server. Nucleic Acids Res. 37:W474-W479.
31. Thullier P, Chahboun S, Pelat T. 2010. A comparison of human and macaque (Macaca mulatta) immunoglobulin germline V regions and its implications for antibody engineering. MAbs 2:528-538.
32. Traggiai E, et al. 2004. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10:871-875.
33. van Gils MJ, et al. 2011. Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies. J. Virol. 85:6986-6995.
34. Walker LM, et al. 2010. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 6:e1001028. doi:10.1371/journal.ppat.1001028.
35. Wei X, et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312.
36. Xu JL, Davis MM. 2000. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity 13:37-45.
37. Yamagami J, et al. 2010. Homologous regions of autoantibody heavy chain complementarity-determining region 3 (H-CDR3) in patients with pemphigus cause pathogenicity. J. Clin. Invest. 120:4111-4117.
38. Yusim K, et al. (ed). 2011. HIV molecular immunology. LA-UR-12-10074. Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, NM.
39. Yuste E, et al. 2008. Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies. J. Virol. 82:12472-12486.